Thursday, 15 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 10, 2025

RadNet raises 2025 revenue guidance as advanced imaging volumes and digital health drive growth

View original at seekingalpha.com
RadNet raises 2025 revenue guidance as advanced imaging volumes and digital health drive growth Earnings Call Insights: RadNet, Inc. (RDNT) Q3 2025 MANAGEMENT VIEW * CEO Howard Berger opened by stating, "I am very pleased with the performance in the third quarter…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Aggregate MRI volume increased 14.8%, CT volume increased 9.4%, and PET/CT volume increased 21.1% from Q3 2024.

    80% confidence
  • RadNet increased imaging center revenue guidance by $50 million at the low end and $30 million at the high end, and increased adjusted EBITDA guidance by $5 million at both ends.

    80% confidence
  • RadNet operates 407 centers as of September 30, 2025, with one new center opened during Q3 and 4.9% total same-center procedure volume growth.

    80% confidence
  • Digital Health revenue increased 51.6% from Q3 2024, partially due to iCAD's revenue contribution since July 17 acquisition.

    80% confidence
  • PET/CT growth is driven by PSMA and amyloid brain studies, which now make up 20% of PET/CT volume.

    80% confidence
  • Labor markets for radiology technologists remain challenging but have stabilized, and RadNet is seeing increasing inbound calls from health systems for partnership opportunities.

    80% confidence
  • Virtual radiology is an inevitability, and DeepHealth serves as a platform to bundle and integrate multiple AI modules for both internal and external customers.

    80% confidence
  • Total company revenue increased 13.4% and adjusted EBITDA increased 15.2% relative to Q3 2024, resulting in a 26 basis point improvement in adjusted EBITDA margins.

    80% confidence
  • Adjusted EBITDA margins increased by 26 basis points from 16% to 16.2% year-over-year.

    80% confidence
  • See-Mode's thyroid ultrasound technology achieved a 30% reduction in scan time across 240+ centers.

    80% confidence
  • Advanced imaging volumes increased 13.0% on an aggregate basis and 9.9% on a same-center basis, driven by equipment upgrades, AI-driven scheduling, capacity expansion, and shift from hospital to ambulatory imaging.

    80% confidence
  • 2026 Medicare reimbursement changes will benefit RadNet with approximately $4-5 million revenue uplift on roughly $2 billion of revenue.

    80% confidence
  • Cash balance as of September 30, 2025 was $804.7 million with net debt to adjusted EBITDA ratio of approximately 1.0.

    80% confidence
  • iCAD contributed approximately $3.9 million in revenue during Q3 2025.

    80% confidence
  • EBCD payer adoption discussions are progressing positively with increasing traction, though large payers move slowly.

    80% confidence
  • RadNet needs more sales personnel post-iCAD acquisition, and margin expansion will increasingly be driven by digital health tools.

    80% confidence
  • Exposure to Medicaid and health insurance exchanges is minimal, reducing risk from policy changes.

    80% confidence
  • EBCD AI revenue rose 28.7% year-over-year.

    80% confidence
  • AI revenue within Digital Health, inclusive of iCAD revenue from ProFound AI and Deep Health solutions, increased 112% from Q3 2024.

    80% confidence
  • DSOs (Days Sales Outstanding) reduced to 31.9 days, the lowest historical level for RadNet.

    80% confidence
  • TechLive rollout should be substantially complete by the end of 2025, and has reduced exam closure hours by about 42% relative to last year.

    80% confidence
  • Q3 2025 revenue and adjusted EBITDA were both quarterly records and exceeded internal budgets set at the beginning of 2025.

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com